Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

Cancer

Volumn 123, Issue 22, 2017, Pages 4391-4402

  Jain, Preetesh ^a   Kantarjian, Hagop M ^a   Ghorab, Ahmad ^a   Sasaki, Koji ^a   Jabbour, Elias J ^a   Nogueras Gonzalez, Graciela ^a   Kanagal Shamanna, Rashmi ^a   Issa, Ghayas C ^a   Garcia Manero, Guillermo ^a   Devendra, K C ^a   Dellasala, Sara ^a   Pierce, Sherry ^a   Konopleva, Marina ^a   Wierda, William G ^a   Verstovsek, Srdan ^a   Daver, Naval G ^a   Kadia, Tapan M ^a   Borthakur, Gautam ^a   O'Brien, Susan ^a,b   Estrov, Zeev ^a   Ravandi, Farhad ^a   Cortes, Jorge E ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

blast phase (BP); bosutinib; chronic myeloid leukemia (CML); dasatinib; imatinib; nilotinib; ponatinib; tyrosine kinase inhibitors (TKI)

Indexed keywords

BOSUTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; GEMTUZUMAB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TROXACITABINE; VINCRISTINE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME 15; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; FAILURE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLAST CELL CRISIS; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85026356485     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30864     Document Type: Article

References (30)

1. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29:1336-1343.
2. Perez-Jacobo F, Tuna-Aguilar E, Demichelis-Gomez R, et al. Prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey. Clin Lymphoma Myeloma Leuk. 2015;15:778-784.
3. Hehlmann R, Saussele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29:295-307.
4. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-454.
5. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333-2340.
6. Jabbour EJ, Hughes TP, Cortes JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014;55:1451-1462.
7. Jiang H, Xu LP, Liu DH, et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant. 2014;49:1146-1154.
8. Kruger P, Cooney J, Nivison-Smith I, et al. All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand. Bone Marrow Transplant. 2016;51:1400-1403.
9. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014;120:373-380.
10. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213.
11. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884.
12. Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742-2750.
13. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044-1054.
14. Oyekunle A, Zander AR, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2013;92:487-496.
15. Saussele S, Lauseker M, Gratwohl A, et al; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880-1885.
16. Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122:3650-3656.
17. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120:2254-2264.
18. Schmidt M, Rinke J, Schafer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28:2292-2299.
19. Kim T, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129:38-47.
20. El Rassi F, Bergsagel JD, Arellano M, et al. Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? Cancer. 2015;121:872-875.
21. Marum JE, Wang PP, Stangl D, et al. Novel fusion genes at CML diagnosis reveal a complex pattern of genomic rearrangements and sequence inversions associated with the Philadelphia chromosome in patients with early blast crisis. Blood. 2016;128:1219. ASH Annual Meeting Abstract.
22. Menezes J, Salgado RN, Acquadro F, et al. ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia. Blood Cancer J. 2013;3:e157.
23. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25:557-560.
24. Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009;114:2037-2043.
25. Yin CC, Abruzzo LV, Qiu X, et al. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009;192:18-23.
26. Ma W, Stafford LJ, Li D, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem. 2007;100:1376-1386.
27. Wang W, Cortes JE, Lin P, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126:1699-1706.
28. Pietarinen PO, Pemovska T, Kontro M, et al. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J. 2015;5:e309.
29. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013;2013:189-200.
30. Carter BZ, Mak PY, Mu H, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8:355ra117.